These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 3986737)

  • 21. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
    Schröder FH; Collette L; de Reijke TM; Whelan P
    Br J Cancer; 2000 Jan; 82(2):283-90. PubMed ID: 10646878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of severe hirsutism resulting from hyperandrogenism with the reverse sequential cyproterone acetate regimen.
    Garner PR; Poznanski N
    J Reprod Med; 1984 Apr; 29(4):232-6. PubMed ID: 6232380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of virginal prostatic cancer with cyproterone acetate].
    Maier U
    Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-androgenic steroid cyproterone acetate. Clinical pharmacology and therapeutic use in hirsutism and acne].
    van Wayjen RG; van den Ende A
    Ned Tijdschr Geneeskd; 1976 Jan; 120(5):189-95. PubMed ID: 129710
    [No Abstract]   [Full Text] [Related]  

  • 25. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
    Varenhorst E; Wallentin L; Carlström K
    Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
    O'Brien RC; Cooper ME; Murray RM; Seeman E; Thomas AK; Jerums G
    J Clin Endocrinol Metab; 1991 May; 72(5):1008-13. PubMed ID: 1827125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of PRL secretion by combined treatment with cyproterone acetate and ethinylestradiol.
    Valenti G; Vescovi PP; Gerra G; Rastelli G; Butturini U
    J Endocrinol Invest; 1985 Jun; 8(3):269-72. PubMed ID: 3161934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease.
    Couzinet B; Le Strat N; Brailly S; Schaison G
    J Clin Endocrinol Metab; 1986 Oct; 63(4):1031-5. PubMed ID: 2943752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prolactin and estradiol levels during hormone therapy of breast cancer].
    Grodecka-Gazdecka S; Chwalisz K; Baron J
    Ginekol Pol; 1985 Apr; 56(4):195-201. PubMed ID: 4043797
    [No Abstract]   [Full Text] [Related]  

  • 30. Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate.
    Robinson MR
    Prog Clin Biol Res; 1987; 243A():383-90. PubMed ID: 2958863
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical results and hormonal aspects of the treatment of virilizing symptoms in women with cyproterone acetate (author's transl)].
    Abrahamsson L; Hackl H; Sogn J; Stafsnes H
    Wien Klin Wochenschr; 1979 Feb; 91(4):126-30. PubMed ID: 154778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial.
    Ostri P; Bonnesen T; Nilsson T; Frimodt-Møller C
    Urol Int; 1991; 46(2):167-71. PubMed ID: 1711250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of prostatic carcinoma with cyproterone acetate.
    Tveter KJ; Otnes B; Hannestad R
    Scand J Urol Nephrol; 1978; 12(2):115-8. PubMed ID: 694435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hormonal treatment of disseminated male breast cancer.
    Lopez M; Di Lauro L; Lazzaro B; Papaldo P
    Oncology; 1985; 42(6):345-9. PubMed ID: 2933617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hirsutism by oral cyproterone acetate and percutaneous estradiol.
    Kuttenn F; Rigaud C; Wright F; Mauvais-Jarvis P
    J Clin Endocrinol Metab; 1980 Nov; 51(5):1107-11. PubMed ID: 6448264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evaluation of the role of androgens in hirsutism and the use of a new anti-androgen "cyproterone acetate" for therapy.
    Ismail AA; Davidson DW; Souka AR; Barnes EW; Irvine WJ; Kilimnik H; Vanderbeeken Y
    J Clin Endocrinol Metab; 1974 Jul; 39(1):81-95. PubMed ID: 4835125
    [No Abstract]   [Full Text] [Related]  

  • 37. [Serum testosterone determination in the antiandrogen therapy of sexual deviations with cyproterone acetate (preliminary report of experiences)].
    Glander HJ; Sorger D
    Psychiatr Neurol Med Psychol (Leipz); 1984 Oct; 36(10):596-603. PubMed ID: 6240067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of cyproterone acetate in the treatment of acne].
    Piquero Martín J; Acosta H
    Med Cutan Ibero Lat Am; 1982; 10(4):261-6. PubMed ID: 6222232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17 beta-estradiol.
    Jasonni VM; Bulletti C; Naldi S; Di Cosmo E; Cappuccini F; Flamigni C
    Fertil Steril; 1991 Apr; 55(4):742-5. PubMed ID: 1826278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cyproterone acetate. 15 cases of hirsutism treated for 1 year].
    Houdent C; Kuhn JM; Balacheff O; Leclerc P; Legrand A; Wolf LM
    Ann Endocrinol (Paris); 1983; 44(6):397-401. PubMed ID: 6234850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.